A community portal about Irritable bowel syndrome with blogs, videos, and photos. According to Wikipedia.org: In gastroenterology, irritable bowel syndrome or spastic colon is a functional bowel disorder characterized by abdominal pain...
[more]
A community portal about Irritable bowel syndrome with blogs, videos, and photos. According to Wikipedia.org: In gastroenterology, irritable bowel syndrome or spastic colon is a functional bowel disorder characterized by abdominal pain and changes in bowel habits which are not associated with any abnormalities seen on routine clinical testing. It is fairly common and makes up 20–50% of visits to gastroenterologists. Lower abdominal pain, and bloating associated with alteration of bowel habits and abdominal discomfort relieved with defecation are the most frequent symptoms. The abdominal pain type is usually described in a patient as either diarrhea -predominant, constipation -predominant or IBS with alternating stool pattern. In some individuals, IBS may have an acute onset and develop after an infectious illness characterised by two or more of the following: fever, vomiting, acute diarrhea, positive stool culture. This post-infective syndrome has consequently been termed "post-infectious IBS" and is acute onset Rome II criteria positive. This condition is more homogenous, being mostly IBS-D and is drawing much clinical investigation.
Seattle, WA (PRWEB) December 22, 2009 -- HelpForIBS.com's Irritable Bowel Syndrome Newsletter has been called "the best available IBS news source with a uniquely empathetic patient focus." The IBS Newsletter is approaching its 200th issue, is offered ...
Background:
A growing amount of scientific evidence suggests that microbes are involved in the aetiology of irritable bowel syndrome (IBS), and the gastrointestinal (GI) microbiota of individuals suffering from diarrhoea-predominant IBS (IBS-D) is distinguishable from other IBS-subtypes. In our study, the GI microbiota of IBS-D patients was evaluated and compared with healthy controls (HC) by using a high-resolution sequencing method. The...
Irritable Bowel Syndrome (IBS) is an ordinary disorder of the bowel that can lead to gassiness, bloating, cramps and frequent visit to the bathroom So if you are lucky enough to be experiencing any of these symptoms, dont fret, it can be cure in just a week
Neither ulcerative colitis nor Crohn's disease should be confused with irritable bowel syndrome (IBS), a disorder that affects the ... CCFA's continuing research efforts, much more will be learned and a cure will eventually be found. How Common is ...
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). The purpose of the meeting was to discuss the completion of the Company’s non-C IBS Development Program, the results of...
International gastroenterology and microbiology experts were invited by Institut Rosell-Lallemand to share and discuss with representatives from the pharma and health care industry the latest research on probiotics in irritable bowel syndrome (IBS)
THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. , announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented...
MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA).
Background:
Functional abdominal pain syndrome (FAPS) has chronic unexplained abdominal pain and is similar to the psychiatric diagnosis of somatoform pain disorder. A patient with irritable bowel syndrome (IBS) also has chronic unexplained abdominal pain, and rectal hypersensitivity is observed in a majority of the patients. However, no reports have evaluated the visceral sensory function of FAPS precisely. We aimed to test the hypothesis...
Ironwood Receives $75M from Astellas for IBS DrugOneMedPlace (blog)While it may not be fatal, irritable bowel syndrome (IBS) ranks high in discomfort and embarrassment. The chronic gastrointestinal disorder is characterized ...Astellas Enters Asian Licensing Agreement for Ironwood's Phase III IBS Therapy ...Genetic Engineering News (press release)Almirall announces a US$ 15 M equity investment in Ironwood Pharmaceuticals ...PharmaLive.com...
Valeant Pharma begins selling generic IBS drugThe Associated PressALISO VIEJO, Calif. — Valeant Pharmaceuticals said Monday it began selling a generic version of Librax, a treatment for irritable bowel syndrome drug. ...Valeant Launching Generic Digestive DrugOrange County Business JournalOceanside Pharma Unveils Launch Of Generic Version Of Librax AG - Quick FactsRTT NewsOceanside Pharmaceuticals Announces Launch of Librax(R) AGPR Newswire...
Ironwood Pharmaceuticals is gearing up for the possibility of an IPO. The Cambridge, MA-based developer of a new treatment for bowel disorders like for irritable bowel syndrome and chronic constipation said it may raise as much as $172.5 million from investors through the deal, according to a prospectus filed late today.
The proposed offering would be [...]
Astellas buys Japan, other rights to new IBS drugReuters... Tuesday it will buy the rights to develop and sell US firm Ironwood Pharmaceuticals' drug for irritable bowel syndrome in Japan and other parts of Asia. ...and more »
Cambridge, MA-based Ironwood Pharmaceuticals, the developer of a treatment for chronic constipation and irritable bowel syndrome, has formed a partnership with Japan-based Astellas Pharma to market the drug in Japan and certain other countries in Asia.
Ironwood will get $75 million in upfront and pre-commercial milestone payments as well as escalating royalties on sales in the [...]
Now, that's irritatingExpress BuzzIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder. Also called spastic colon, it is a functional bowel disorder characterised by ...